Travere Therapeutics, Inc.
TVTX
$26.02
-$0.05-0.19%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/10/2025
-
MarketBeat
10/9/2025
-
Simply Wall St
10/8/2025
-
Simply Wall St
Travere Therapeutics (TVTX, $26.13) price may drop as it broke higher Bollinger Band on Oct 06, 2025
10/7/2025
-
Tickeron - Technical Analysis
10/4/2025
-
Tickeron - Stocks
10/1/2025
-
MarketBeat
10/1/2025
-
The Fly
10/1/2025
-
MarketBeat
9/29/2025
-
MarketBeat
9/27/2025
-
Simply Wall St
9/26/2025
-
GuruFocus
9/26/2025
-
Business Wire
9/26/2025
-
Tickeron - Technical Analysis
9/26/2025
-
GuruFocus
9/26/2025
-
PR Newswire
9/26/2025
-
CNW Group - News Releases
9/25/2025
-
MarketBeat
9/25/2025
-
Ticker Report
9/25/2025
-
Tickeron - Stocks
9/24/2025
-
MarketBeat
9/22/2025
-
Ticker Report
9/21/2025
-
Simply Wall St
9/20/2025
-
MarketBeat
9/20/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, August 6, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Oct 27 and 31 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
888 969 7879
Address
3611 Valley Centre Drive
San Diego, CA 92130
San Diego, CA 92130
Country
Year Founded
Business Description
Sector
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s...
more